Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
Oncogenic osteomalacia (OOM) is characterised by tumour production of fibroblast growth factor 23 (FGF23) that results in hypophosphataemia and renal phosphate wasting, reduced 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) synthesis and osteomalacia. Here, we demonstrate the roles of serum FGF23 and 1,25(O...
Main Authors: | Hannan, F, Athanasou, N, Teh, J, Gibbons, C, Shine, B, Thakker, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2008
|
Similar Items
-
A Rare Case of Hypophosphataemic Osteomalacia in von Recklinghausen Neurofibromatosis
by: Yasmine Makhlouf, et al.
Published: (2021-05-01) -
THE PRODUCTION OF 1,25-DIHYDROXYVITAMIN-D IN PRIMARY HYPERPARATHYROIDISM
by: Thakker, R, et al.
Published: (1986) -
Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia
by: Amarnani, R, et al.
Published: (2020) -
Treating ‘osteoporosis’: a near miss in an unusual case of FGF-23-mediated hypophosphataemic osteomalacia
by: Mike Lin, et al.
Published: (2022-11-01) -
Circulating concentrations of 1,25-dihydroxyvitamin D3 in patients with primary hyperparathyroidism.
by: Thakker, R, et al.
Published: (1986)